MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1182/blood.2022016934

Медицинская библиотека · Blood · 2023

NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts.

Zhang Deyi, Harris Hailey M, Chen Jonathan, Judy Jen, James Gabriella, Kelly Aileen, McIntosh Joel, Tenn-McClellan Austin, Ambing Eileen, Tan Ying Siow, Lu Hao, Gajewski Stefan, Clifton Matthew C, Yung Stephanie, Robbins Daniel W, Pirooznia Mehdi, Skånland Sigrid S, Gaglione Erika, Mhibik Maissa, Underbayev Chingiz, Ahn Inhye E, Sun Clare, Herman Sarah E M, Noviski Mark, Wiestner Adrian

СтатьяПеревод пока не подготовлен

Аннотация

Bruton tyrosine kinase (BTK) is essential for B-cell receptor (BCR) signaling, a driver of chronic lymphocytic leukemia (CLL). Covalent inhibitors bind C481 in the active site of BTK and have become a preferred CLL therapy. Disease progression on covalent BTK inhibitors is commonly associated with C481 mutations. Here, we investigated a targeted protein degrader, NRX-0492, that links a noncovalent BTK-binding domain to cereblon, an adaptor protein of the E3 ubiquitin ligase complex. NRX-0492 selectively catalyzes ubiquitylation and proteasomal degradation of BTK. In primary CLL cells, NRX-0492 induced rapid and sustained degradation of both wild-type and C481 mutant BTK at half maximal degradation concentration (DC50) of ≤0.2 nM and DC90 of ≤0.5 nM, respectively. Sustained degrader activity was maintained for at least 24 hours after washout and was equally observed in high-risk (deletion 17p) and standard-risk (deletion 13q only) CLL subtypes. In in vitro testing against treatment-naïve CLL samples, NRX-0492 was as effective as ibrutinib at inhibiting BCR-mediated signaling, transcriptional programs, and chemokine secretion. In patient-derived xenografts, orally administered NRX-0492 induced BTK degradation and inhibited activation and proliferation of CLL cells in blood and spleen and remained efficacious against primary C481S mutant CLL cells collected from a patient progressing on ibrutinib. Oral bioavailability, >90% degradation of BTK at subnanomolar concentrations, and sustained pharmacodynamic effects after drug clearance make this class of targeted protein degraders uniquely suitable for clinical translation, in particular as a strategy to overcome BTK inhibitor resistance. Clinical studies testing this approach have been initiated (NCT04830137, NCT05131022).

Для цитирования: Zhang Deyi, Harris Hailey M, Chen Jonathan, Judy Jen, James Gabriella, Kelly Aileen, McIntosh Joel, Tenn-McClellan Austin, Ambing Eileen, Tan Ying Siow, Lu Hao, Gajewski Stefan, Clifton Matthew C, Yung Stephanie, Robbins Daniel W, Pirooznia Mehdi, Skånland Sigrid S, Gaglione Erika, Mhibik Maissa, Underbayev Chingiz, Ahn Inhye E, Sun Clare, Herman Sarah E M, Noviski Mark, Wiestner Adrian. NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts.. Blood. 2023. DOI: 10.1182/blood.2022016934.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.